Bausch Health’s $7.9 Billion Refinancing Move Is An Effort Towards A Financial Comeback; Will It Work? 

Bausch Health Companies Inc. recently reported strong second-quarter results for 2025, building on its record of consecutive revenue and adjusted EBITDA growth. The company delivered a 5% year-over-year increase in revenue, reaching $1.252 billion, and a 10% increase in adjusted EBITDA. This performance was driven by double-digit growth in the Salix and Solta segments, along with robust results in Europe, the Middle East, Africa (EMEA), and Canada. These results are notable, particularly given the uncertainty in the macroeconomic environment.